Topics

Phase 2 Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic ACC

2019-10-15 11:11:26 | BioPortfolio

Summary

This is a Phase 2, multicenter, open-label, single-arm study of rivoceranib to evaluate its efficacy and safety in adult subjects with metastatic ACC of all anatomic sites of origin.

Study Design

Conditions

ACC

Intervention

Rivoceranib

Status

Not yet recruiting

Source

LSK BioPartners Inc.

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-10-15T11:11:26-0400

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Phase 1b/2 Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer

Comparing the efficacy of rivoceranib and trifluridine/tipiracil administered individually as monotherapies, as well as a rivocernib plus trifluridine/tipiracil combination therapy in the ...

Safety, Tolerability and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced GC or GEJ Cancer.

This is an open-label, single-center, single-arm, dose escalation and dose expansion Phase I/IIa study designed to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (...

PubMed Articles [0 Results]

None

Medical and Biotech [MESH] Definitions

None available.

More From BioPortfolio on "Phase 2 Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic ACC"

Quick Search

Searches Linking to this Trial